Korsana Biosciences Inc. has emerged from stealth, with its development of therapeutics to treat neurodegenerative diseases initially focused on Alzheimer’s disease.

Asahi Kasei Pharma Corp. has advanced its novel endothelin ETA receptor antagonist AK-1960 into phase I in Japan for the treatment of various refractory diseases, such as chronic kidney disease.

Building on the foundation laid in 2020, researchers at the University of California, San Francisco (UCSF) have now shown that targeting the GPI-anchored vascular enzyme TNAP can reproduce the cognitive benefits previously attributed to the liver-derived exercise factor GLPD1.

In the inflamed joints of rheumatoid arthritis, CD4+ T lymphocytes accumulate lipid droplets that make them vulnerable and promote their death, thereby amplifying joint inflammation. A study led by scientists at Mayo Clinic and Stanford University suggests that blocking the formation of these lipid droplets or their contents could offer a therapeutic strategy for this condition.

A project that started as a bioreactor to assist astronauts in deep space to keep medications safe in a microgravity environment could help pharma companies model how drugs behave in the human body. Omnigeniq unveiled at the J.P. Morgan Healthcare conference the first computer model of a human protein as it exists in the body, confirming that native protein topology can be calculated directly from physics.